Log In Sign up
The largest database of trusted experimental protocols

Plx4032

Manufactured by Plexxikon
Visit Supplier
Sourced in United States

PLX4032 is a laboratory equipment product. It is designed for scientific research and analysis purposes. The core function of PLX4032 is to provide a controlled environment for conducting various experiments and tests. Further details about its intended use or performance are not available.

Automatically generated - may contain errors

Lab products found in correlation

Azd6244, by Selleck Chemicals (2 mentions) Cobimetinib, by Selleck Chemicals (1 mentions) Sch772984, by Chemietek (1 mentions) Binimetinib, by LC Laboratories (1 mentions) Crizotinib, by Selleck Chemicals (1 mentions) Hepatocyte growth factor (hgf), by Thermo Fisher Scientific (1 mentions) Chir99021, by Bio-Techne (1 mentions) Cas9 plasmid, by Addgene (1 mentions) Abt 888, by Enzo Life Sciences (1 mentions) Amg510, by Selleck Chemicals (1 mentions) Mrtx849, by Selleck Chemicals (1 mentions) Nu7026, by Abcam (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Trametinib, by LC Laboratories (1 mentions) Olaparib, by LC Laboratories (1 mentions) Fb 02, by Omega Scientific (1 mentions) Geneprint 10 system, by Promega (1 mentions)

4 protocols using plx4032

1

Lentiviral Knockdown and Overexpression

Cited 4 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
shNRAS, shCRAF, shBRAF were sub-cloned into the lentiviral vector pLL3.7 as described (4 (link),7 (link),29 (link),40 (link)). NRAS over-expression and all knockdown constructs were packaged into lentiviral particles for infection. Experiments were carried out 3 days post-transduction. Inhibitors were obtained from the following sources: PLX4032 (Plexxikon), trametinib in vitro and in vivo (LC Laboratories), BGB-283 and BGB-3245 (Beigene), RAF709 (Cayman Chemical), LXH254 (Selleckchem), cobimetinib (Selleckchem), binimetinib (LC Laboratories), and SCH772984 (Chemietek).
Hong A., Piva M., Liu S., Hugo W., Lomeli S.H., Zoete V., Randolph C.E., Yang Z., Wang Y., Lee J.J., Lo S.J., Sun L., Vega-Crespo A., Garcia A.J., Shackelford D.B., Dubinett S.M., Scumpia P.O., Byrum S.D., Tackett A.J., Donahue T.R., Michielin O., Holmen S.L., Ribas A., Moriceau G, & Lo R.S. (2020). Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. Cancer discovery, 11(3), 714-735.
+ Open protocol
+ Expand
2

Combinatorial Drug Screening in Melanoma

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell lines were maintained in DMEM with 10% heat-inactivated FBS, 2 mmol/L glutamine in a humidified 5% CO2 incubator. Stocks and dilutions of crizotinib (Selleck Chemicals), PLX4032 (Plexxikon, Berkeley, CA, USA), AZD6244 (Selleck Chemicals), and CHIR99021 (Tocris Bioscience) were made in DMSO. HGF (Life technologies) was suspended in PBS. MTT and clonogenic assays were performed and quantified as described (Moriceau et al., 2015 (link)). shc-METs were cloned using the pLL3.7-GFP vector (sequences available upon request); shYAP1s were purchased from GE Dharmacon (vector pLK0.1); and LEF1, YAP1 and NRAS WT or Q61R were constructed in pRRLsin-cPPT-CMV-IRES-GFP and pLVX-Tight-puro lentiviral vectors.
Hugo W., Shi H., Sun L., Piva M., Song C., Kong X., Moriceau G., Hong A., Dahlman K.B., Johnson D.B., Sosman J.A., Ribas A, & Lo R.S. (2015). Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell, 162(6), 1271-1285.
+ Open protocol
+ Expand
3

MiniCoopr Transgenic Cell Line Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasmids used for the MiniCoopr transgenics were obtained as a gift
from Yariv Houvras (Weill-Cornell Medical College). The Cas9 plasmid was
obtained from Addgene (#42251). All cell culture media (as outlined in the Supplemental Methods)
were obtained from Life Technologies. PLX4032 was a gift from Plexxikon, and
CI1040 was obtained from Selleckchem (Catalog number S1020).
Heilmann S., Ratnakumar K., Langdon E., Kansler E., Kim I., Campbell N.R., Perry E., McMahon A., Kaufman C., van Rooijen E., Lee W., Iacobuzio-Donahue C., Hynes R., Zon L., Xavier J, & White R. (2015). A quantitative system for studying metastasis using transparent zebrafish. Cancer research, 75(20), 4272-4282.
+ Open protocol
+ Expand
4

Comprehensive Cell Line Verification and MAPKi Resistance Assays

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All cell lines were routinely tested for Mycoplasma and profiled and identified by RNA-seq and the GenePrint 10 system (Promega) at periodic intervals during the course of this study. All M series cell lines were established from patient-derived tumors at the UCLA with institutional review board approval. All M cell lines with acquired MAPKi resistance were derived in the Lo Laboratory and published previously (3, 5, 8, 9, 11, 22, 40, 67 (link)). We maintained H358 (ATCC) in RPMI 1640 (Gibco) with 10% heat-inactivated FBS (Omega Scientific, FB-02) and 2 mmol/L glutamine in a humidified, 5% CO2 incubator at 37°C; all other cell lines were maintained in high-glucose DMEM (Omega Scientific, DM-22) with 10% heat-inactivated FBS (Omega Scientific, FB-02) and 2 mmol/L glutamine in a humidified, 5% CO2 incubator at 37°C. We obtained inhibitors from the following sources: PLX4032 (Plexxikon), AZD6244 (Selleck Chemicals), trametinib (LC Laboratories), NU7026 (Abcam, ab120970), ABT888 (Enzo, ALX-270-444-M005), VX984 (MCE, HY-19939S), AZD7648 (TargetMol, T7122), olaparib (LC Laboratories, 763113-22–0), MRTX849 (Selleckchem, S8884), AMG510 (Selleckchem, S8830), and BGB-283 (BeiGene, via a Material Transfer Agreement with UCLA). All inhibitors were dissolved in DMSO and stored at −20°C.
Dharanipragada P., Zhang X., Liu S., Lomeli S.H., Hong A., Wang Y., Yang Z., Lo K.Z., Vega-Crespo A., Ribas A., Moschos S.J., Moriceau G, & Lo R.S. (2023). Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. Cancer Discovery, 13(4), 880-909.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!